Dimensional Fund Advisors LP Buys 130,921 Shares of Bio-Rad Laboratories, Inc. $BIO

Key Points

• Dimensional Fund Advisors LP has increased its stake in Bio-Rad Laboratories by 17.5%, now owning approximately 3.13% of the company valued at $213.6 million.
• Bio-Rad's stock price has seen a slight decline of 0.4% recently, and its latest earnings report showed earnings per share of $2.61, exceeding the consensus estimate.
• Analysts are optimistic about Bio-Rad, with a consensus rating of "Moderate Buy" and an average price target of $333.50.

Dimensional Fund Advisors LP lifted its position in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 17.5% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 877,040 shares of the medical research company's stock after buying an additional 130,921 shares during the quarter. Dimensional Fund Advisors LP owned about 3.13% of Bio-Rad Laboratories worth $213,608,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Lecap Asset Management Ltd. lifted its holdings in Bio-Rad Laboratories by 3.1% during the 1st quarter. Lecap Asset Management Ltd. now owns 1,600 shares of the medical research company's stock valued at $390,000 after purchasing an additional 48 shares during the last quarter. State of Alaska Department of Revenue lifted its holdings in Bio-Rad Laboratories by 2.5% during the 1st quarter. State of Alaska Department of Revenue now owns 2,254 shares of the medical research company's stock valued at $548,000 after purchasing an additional 55 shares during the last quarter. ProShare Advisors LLC lifted its holdings in Bio-Rad Laboratories by 8.0% during the 4th quarter. ProShare Advisors LLC now owns 901 shares of the medical research company's stock valued at $296,000 after purchasing an additional 67 shares during the last quarter. GeoWealth Management LLC lifted its holdings in Bio-Rad Laboratories by 342.9% during the 4th quarter. GeoWealth Management LLC now owns 93 shares of the medical research company's stock valued at $31,000 after purchasing an additional 72 shares during the last quarter. Finally, Commerce Bank lifted its holdings in Bio-Rad Laboratories by 11.7% during the 4th quarter. Commerce Bank now owns 801 shares of the medical research company's stock valued at $263,000 after purchasing an additional 84 shares during the last quarter. 65.24% of the stock is owned by institutional investors.

Bio-Rad Laboratories Stock Performance

Shares of BIO traded up $17.96 during midday trading on Friday, reaching $302.99. 783,331 shares of the stock were exchanged, compared to its average volume of 299,085. The company has a quick ratio of 3.67, a current ratio of 5.12 and a debt-to-equity ratio of 0.17. Bio-Rad Laboratories, Inc. has a twelve month low of $211.43 and a twelve month high of $387.99. The company has a market cap of $8.20 billion, a P/E ratio of 25.83 and a beta of 0.90. The stock's 50 day simple moving average is $257.27 and its 200 day simple moving average is $253.32.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last issued its quarterly earnings results on Thursday, July 31st. The medical research company reported $2.61 EPS for the quarter, topping analysts' consensus estimates of $1.93 by $0.68. Bio-Rad Laboratories had a return on equity of 4.01% and a net margin of 12.50%.The company had revenue of $651.60 million for the quarter, compared to analysts' expectations of $614.82 million. During the same quarter last year, the business earned $3.11 earnings per share. Bio-Rad Laboratories's revenue was up 2.1% on a year-over-year basis. Bio-Rad Laboratories has set its FY 2025 guidance at EPS. On average, sell-side analysts expect that Bio-Rad Laboratories, Inc. will post 10.81 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts have issued reports on BIO shares. Wells Fargo & Company raised their price target on Bio-Rad Laboratories from $245.00 to $265.00 and gave the company an "equal weight" rating in a report on Friday, August 1st. Royal Bank Of Canada raised their price target on Bio-Rad Laboratories from $387.00 to $409.00 and gave the company an "outperform" rating in a report on Friday, August 1st. Wall Street Zen downgraded Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a report on Friday. Citigroup cut their price target on Bio-Rad Laboratories from $400.00 to $350.00 and set a "buy" rating for the company in a report on Friday, May 2nd. Finally, UBS Group dropped their target price on Bio-Rad Laboratories from $355.00 to $310.00 and set a "buy" rating for the company in a report on Friday, May 2nd. Three equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $333.50.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.